Clinical reference Biomarker Directory
Back to directory

IL6

Emerging

IL-6 is the central driver cytokine in CAR-T-related cytokine release syndrome, treated first-line with tocilizumab.

Also known as IL-6 interleukin-6
In plain language

IL-6 is a key driver of a dangerous inflammatory reaction that can happen after certain cancer immunotherapies (CAR-T cell therapy). A drug that blocks IL-6's receptor is now the standard treatment for this reaction, and the same drug became widely used during severe COVID-19 cases too.

Biomarker & context

Interleukin-6 (IL-6) is a pro-inflammatory cytokine central to the acute-phase response and a key driver of cytokine release syndrome (CRS), a serious complication of CAR-T cell therapy and certain other immunotherapies.

What it indicates

IL-6 is considered the primary cytokine driving CRS symptoms (fever, hypotension, hypoxia) after CAR-T cell infusion; current guidelines recommend tocilizumab (an IL-6 receptor antagonist) as first-line treatment for grade 2 or higher CRS.

Diagnosis & clinical testing

Measured via serum immunoassay; IL-6 levels can help guide the timing of tocilizumab administration in CRS management, though clinical grading criteria (based on fever, hypotension, and hypoxia severity) generally drive treatment decisions more than the absolute IL-6 level itself.

Guiding treatment

Tocilizumab is now standard first-line therapy for grade ≥2 CRS following CAR-T therapy; the same drug class saw major expanded use in severe COVID-19-associated cytokine storm, reflecting IL-6's central role across multiple hyperinflammatory conditions.

Clinical significance

The same IL-6-blocking drug class saw major expanded use in severe COVID-19-associated cytokine storm.

References
  1. General hematology/oncology reference literature on IL-6 in cytokine release syndrome and tocilizumab treatment guidelines.